"Biden Administration Cracks Down on Drugmakers with Inflation Penalties"
The Biden administration has identified 48 drugs in the Medicare program whose prices rose faster than inflation during the fourth quarter of the year and may require their makers to pay rebates. Medicare recipients could benefit from reduced co-insurance payments for these drugs. The administration aims to save $25 billion annually by 2031 by requiring drugmakers to negotiate prices with Medicare. The White House is emphasizing the benefits of the Inflation Reduction Act in bringing down drug prices ahead of the 2024 election. Additionally, the administration announced guidelines for potentially seizing patents for medicines developed with government funding if their prices are deemed too high.
